-
HABITS was a randomized but not placebo-controlled trial in which hormone therapy was compared to management without hormones in women with menopausal symptoms who had been previously treated for Stage I or Stage II breast cancer.1 Concomitant tamoxifen treatment was allowed in the HABITS patients but not aromatase inhibiters.
-
The authors set out to determine the preventive services and counseling provided by gynecologists, general medical physicians, or both. Using the 2000 National Health Interview Survey, the study population included women aged 18-64 years of age (with regard to Pap smear, use of tobacco, and exercise/diet counseling) and women in the 50-64 age group (previous parameters plus breast examinations, mammograms, and colon cancer screening). Sixty-two percent of patients were seen by gynecologists, 15% by general medical physicians, and 23% by both.
-
Cuppone and colleagues primarily from the Regina Elena National Cancer Institute in Rome, Italy, performed a meta-analysis of randomized trials comparing aromatase inhibitors with tamoxifen in early breast cancer, focusing on cardiovascular risk.
-
Being pregnant puts patients in a special category where, seemingly, everything they put in their mouths, even some foods, has some risk to the fetus.
-
Many pregnant patients ask whether it is bad to exercise regularly and vigorously, while others ask whether exercising in any way helps to improve outcome. These questions were addressed in a recent publication in the American Journal of Obstetrics & Gynecology.
-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
-
The Women's Health Initiative (WHI) is a randomized controlled trial which is evaluating cancer and disease risk among healthy menopausal women aged 50-79 years.
-
By Alison Edelman, MD, MPH, Assistant Professor, Assistant Director of the Family Planning Fellowship Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, is Associate Editor for OB/GYN Clinical Alert.
-
The primary purpose of this phase III study was to determine if maintenance of hemoglobin values above 12 g/dL by use of R-HUEPO during chemoradiotherapy (weekly cisplatin) for advanced cervix cancer was associated with improved outcomes (progression-free and overall survival and local control rates) relative to maintenance of hemoglobin values above 10 g/dL by way of non-R-HUEPO methods.
